BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y(TM) Dosimetry Software in Europe

London (ots/PRNewswire) - New easy-to-use software designed to
improve the planning of 90Y selective internal radiation therapy
(SIRT) treatment for patients with liver cancer

BTG plc (LSE: BTG), an international specialist healthcare company,
with Mirada Medical Ltd, a leading global brand in medical imaging
software, today announced CE Mark certification for Simplicit90Y(TM)
dosimetry software, designed to optimise the planning of 90Y
selective internal radiation therapy (SIRT) and facilitate
personalised treatment for patients with liver cancer. CE Mark
certification follows approval for Simplicit90Y(TM) in Canada.

(Logo: http://photos.prnewswire.com/prnh/20160203/329110LOGO )

BTG, in collaboration with Mirada Medical, have developed
Simplicit90Y(TM) to be a customised, easy-to-use, dosimetry software
developed for rapid 90Y SIRT workflow. Simplicit90Y(TM) provides
digital processing, review and reporting of medical images with
unique options for data display, quality control, image manipulation
and quantification analysis. Together, these features allow for more
standardised and consistent dosimetry planning and post-treatment
validation, and the ability to personalise treatment for each
patient.

"Simplicit90Y(TM) represents an important advance in providing
patients and healthcare providers with added value beyond our
products and we are pleased it has received CE Mark certification,"
commented Zillah Moore, Director Commercial Operations EMEA. "It will
ensure 90Y therapies, such as TheraSphere®, can be specifically
tailored to individual patient needs, facilitating personalised
treatments. Simplicit90Y(TM) will help us offer interventional
oncology teams more power to personalise and optimise 90Y SIRT for
their patients. We're delighted Simplicit90Y(TM) is now available for
physicians to use."

"Dosimetry can be a time intensive and complex process and
Simplicit90Y(TM) simplifies both dosimetry planning and
post-treatment validation," said Etienne Garin, MD, PhD, Chair
professor of Nuclear Medicine, Cancer Institute, Centre Eugene
Marquis Rennes, France. "Knowing you can use this intuitive software
to help deliver a more personalised treatment for each patient,
achieving the best dose of 90Y radiation to the tumour while
minimising exposure to healthy tissue, gives physicians more
confidence."

Matthieu Leclerc-Chalvet, Mirada Medical, Managing Director
commented, "We designed this software to simplify the dosimetry
workflow for SIRT and enhance consistency and efficiency. Mirada
Medical supports 90Y treatment quality by incorporating advanced
image processing tools that facilitate the clinician's use of
multi-modal images to plan 90Y SIRT treatment. Leveraging combined
expertise from across the industry helped meet both the physician's
and patient's needs and Simplicit90Y(TM) is a clear demonstration of
that success."

BTG and Mirada Medical will be at the 29th Annual EANM Congress in
Barcelona, Spain, 15th - 19th of October, 2016. Information regarding
Simplicit90Y(TM) will be available via the BTG booth (#62 & 76) and
Mirada Medical booth (#65 & 66) in the main exhibition hall. For more
information on Simplicit90Y(TM) please visit
http://www.btg-im.com/Simplicit90Y and register your interest.

About Simplicit90YTM

Simplicit90YTM is a standalone software device intended for use by
Nuclear Medicine (NM) or Radiology practitioners for display,
processing and reporting of data, including planar scans (Static,
Whole Body) and tomographic scans acquired by gamma cameras or PET
scanners. Physicians can use the system for viewing and assessing
image data for general clinical diagnostic purposes with additional
features and optimised workflow for yttrium-90 (90Y) dosimetry.

About TheraSphere®

TheraSphere® 90Y glass microspheres are specifically engineered to
carry far greater power than any other 90Y liver-directed cancer
therapy. TheraSphere® works predominantly through radiation, with
minimal embolic effect[1] which allows the microspheres to lodge
deeper inside the tumor, achieving a high absorbed dose. The result
is a powerful, targeted and well-tolerated therapy that may lead to
patients becoming eligible for curative therapies.

In the EU, Singapore, South Korea and Canada, TheraSphere® is
approved for the treatment of hepatic neoplasia. TheraSphere® is
commercially available in Hong Kong and Malaysia. In the US,
TheraSphere® is approved under a Humanitarian Device Exemption (HDE)
for use in radiation treatment or as a neoadjuvant to surgery or
transplantation in patients with unresectable hepatocellular
carcinoma (HCC) who can have placement of appropriately positioned
hepatic arterial catheters. TheraSphere® is also indicated for HCC
patients with partial or branch portal vein thrombosis/occlusion,
when clinical evaluation warrants the treatment. The effectiveness of
TheraSphere® for this use in the US has not been demonstrated. For
full instructions for use and important safety information, please
visit http://www.therasphere.com.

About BTG Interventional Medicine

BTG Interventional Medicine is part of BTG plc, a growing
international specialist healthcare company. As medicine moves from
major surgery to minor procedure, from the systemic to the local, no
company endeavors to do more than BTG Interventional Medicine to help
doctors in their quest to see more, reach further and treat smarter.
Our growing portfolio of Interventional Medicine products is designed
to advance the treatment of cancer tumors, advanced emphysema, severe
blood clots, and varicose veins. To learn more about BTG
Interventional Medicine, please visit: http://www.btg-im.com.

About Mirada Medical Ltd

Mirada Medical is a leading international brand in medical imaging.
The company develops advanced software applications which help
healthcare professionals use medical images more effectively and
efficiently to improve cancer care. Mirada's products are used across
diagnostic radiology, molecular imaging, radiation oncology, medical
oncology, tumour board and elsewhere. Mirada Medical was originally
spun out of the University of Oxford. The company's technologies and
products continue to be developed by their team of specialists,
engineers and world-renowned scientists at Mirada's world
headquarters in Oxford, England. For more information about Mirada
Medical products visit: http://www.mirada-medical.com.

1. Pellerin O, et al. Cancer Biother Radiopharm 2013;28(6):459-65.

ORIGINAL APA-OTS TEXT - THE INFORMATION CONTAINED IN THIS PRESS RELEASE IS SUBJECT TO THE EXCLUSIVE RESPONSIBILITY OF THE ISSUER | PRN

print